{'fraction_non_alphanumeric': 0.024844720496894408, 'fraction_numerical': 0.022774327122153208, 'mean_word_length': 5.205128205128205, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Variations in the behavior in chronic hospitalized schizophrenics under treatment with EMD 16, 139, a benzoquinolizine derivative].

A group of hospitalized chronic schizophrenic patients was treated with EMD 16 139 - a benzochinolizin derivate - for 4 weeks in a placebo-controlled trial. Changes of behavior were measured using a rating scale. The results suggest an increase of activity and initiative during treatment. Problems concerning some neuroleptic effects are discussed.